ArticleJournal of pain research2025
Druggable Genome-Wide Mendelian Randomization Identifies Distinct Therapeutic Targets for Low Back Pain, Intervertebral Disk Degeneration, and Sciatica.
Article in Journal of pain research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: There are no effective drugs for the treatment of low back pain (LBP), intervertebral disk degeneration (IVDD), or sciatica. We aimed to identify potential therapeutic targets through druggable genome-wide Mendelian randomization (MR) analysis. Methods: This study utilized large-scale expression quantitative trait loci (eQTLs) and protein quantitative trait loci (pQTLs), integrating existing druggable genome data. Conducted two-sample MR analysis to estimate the causal relationships between druggable genes with LBP, IVDD, and sciatica. Furthermore, we employed Bayesian colocalization, summary data-based Mendelian randomization (SMR) analysis, and the Steiger filtering test to validate our results and identify therapeutic targets. Additionally, we used a phenome-wide MR approach to assess the side effects or other indications of the identified therapeutic targets. Results: MR analysis identified 10 candidate druggable genes associated with LBP, 18 candidate druggable genes with IVDD, and 8 candidate druggable genes with sciatica. By applying Bayesian colocalization (posterior probability for H4>80%), SMR analysis (P<0.05), and the Steiger filtering test (TRUE), we identified one therapeutic target for LBP (P2RY13), four for IVDD (CAPN10, AKR1C2, BTN1A1, EIF2AK3), and four for sciatica (NT5C, GPX1, SUMO2, DAG1). Phenome-wide MR analysis revealed potential adverse cardiac metabolic effects associated with NT5C. Conclusion: Our study integrated eQTL and pQTL data to identify nine phenotype-specific therapeutic targets for LBP, IVDD, and sciatica. These findings highlight potential candidates for future drug repurposing, experimental validation, and the development of mechanism-based therapies tailored to each condition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.